Clinical Trials Logo
  1. Home
  2. Spinal Muscular Atrophy Type 3
  3. NCT05430113

Spinal Cord Stimulation in Spinal Muscular Atrophy — SCSinSMA  

Spinal Muscular Atrophy Type 3 Clinical Trial

Official title:
Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy

Clinical Trial Summary

Spinal cord stimulation (SCS) has shown remarkable efficacy in restoring motor function in people with spinal cord injury by recruiting afferent input to enhance the responsiveness of spared neural circuits to residual cortical inputs. This pilot will test if SCS can show evidence to improve motor deficits in people with type 3 or 4 spinal muscular atrophy (SMA). The investigators will enroll up to six subjects with Type 3 or 4 SMA aged 16 or older that show quantifiable motor deficits of the legs but are able to stand independently. The investigators will then implant the subjects with percutaneous, bilateral, linear spinal leads near the lumbar spinal cord for a period of up to 29 days. Although these leads are not optimized for motor function but rather for their clinically approved indication of treating pain, the investigators believe they provide a safe technology enabling our team to perform scientific measurement necessary to evaluate potential for effects of SCS in motor paralysis with SMA. After the end of the study, the leads will be explanted.

Clinical Trial Description

The investigators plan to 1. verify that spinal cord stimulation increases hip muscle strength in subjects with SMA, 2. verify that spinal cord stimulation improves motor control in subjects with SMA, 3. verify that spinal cord stimulation induces measurable changes in spinal circuits and motoneuron recruitment properties in the 29 day course of implantation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05430113
Study type Interventional
Source University of Pittsburgh
Contact Sydney Bader, MS
Phone 412-648-4196
Email syb17@pitt.edu
Status Recruiting
Phase N/A
Start date April 5, 2022
Completion date August 2027
View Details
See also
  Status Clinical Trial Phase
Completed NCT04193085 - Wearable Technology to Assess Gait Function in SMA and DMD
Completed NCT02895789 - Oxidative Capacity and Exercise Tolerance in Ambulatory SMA
Not yet recruiting NCT06300996 - Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb N/A
Terminated NCT03819660 - Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3 Phase 2
Recruiting NCT05272969 - Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
Recruiting NCT05544994 - The Effect of Aerobic Exercise Training in Patients With Type III Spinal Muscular Atrophy N/A
Completed NCT02227823 - Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3 Phase 2
Active, not recruiting NCT05156320 - Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam Phase 3
Recruiting NCT03709784 - Spinraza in Adult Spinal Muscular Atrophy
Terminated NCT03056144 - Whole Body Vibration Therapy in Children With Spinal Muscular Atrophy N/A
Completed NCT03921528 - An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy Phase 2
Active, not recruiting NCT05626855 - Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab-ONYX Phase 3
Completed NCT04907162 - Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders